Health and Wellness

AI-powered app enables anemia screening using fingernail selfies

Anemia is a common health condition that affects over 2 billion people globally, with an estimated 83 million Americans at high risk. However, a groundbreaking new app is revolutionizing anemia

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.

Lasted Health and Wellness

Gene Therapy For Inherited Disease In Infants

Advances in medical technology have revolutionized the way we approach inherited diseases, especially in infants. With newborn screening and rapid

Double serving of evidence underscores power of plant-based diet for heart health

The plant-based Portfolio Diet has been making headlines recently, with two new studies showing its effectiveness in reducing the risk

Why Blood Test For Early Detection Of Alzheimer’s Disease Matters

Alzheimer’s disease is a devastating condition that affects millions of individuals in the United States. With symptoms that worsen over

Health Care Inc.: DOGE’s Brad Smith profile, Stephanie Carlton CMS interview

The healthcare industry is an ever-evolving field with constant changes and developments. In this week's edition of Health Care Inc.,

Cannabis use reaches a new high among older adults

The use of marijuana among older adults in the United States has been on the rise, with 7% of adults

Teva’s Layoffs Signal Deeper Fault Lines In The Pharma Business Model

The recent announcement that Teva Pharmaceuticals will lay off roughly 2,400 employees–approximately 8% of its global workforce–is a significant development

Potent sweetener neotame found by researchers in popular vapes

Neotame, a potent artificial sweetener that is 7,000-13,000 times sweeter than sugar, has been found in a variety of products

Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This

Employers in the United States are still hesitant to cover glucagon-like peptide-1 (GLP-1) drugs for weight loss, according to a